Myrbetriq®, Myrbetriq® Granules (mirabegron extended-release) – New indication, new formulation approval
March 26, 2021 - Astellas Pharma announced the FDA approval of Myrbetriq (mirabegron) tablets, for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients aged 3 years and older and weighing 35 kg or more.
Top